Stanford APBI Trial
Clinical Trial
Overview
Accelerated, partial breast irradiation (APBI) is a potentially important new way to incorporate radiotherapy in the treatment of women with breast cancer.
Currently, women with breast cancer who undergo a lumpectomy typically have 6 1/2 weeks of radiation to the entire affected breast after surgery. Accelerated, partial breast irradiation (APBI) changes this approach in two ways. It shortens the treatment time from 6 1/2 weeks to between 1 to 5 days, and reduces the treatment area from the entire breast to the area of the breast immediately around the lumpectomy site. This is the part of the breast where most cancers are likely to recur.
In many ways APBI is to current whole breast radiotherapy what a lumpectomy is to a mastectomy. The goal is to use a less invasive more focused treatment without compromising survival.
APBI has been used in limited trials in several hundred patients over the last 10 years. These trials show that in properly selected breast cancer patients APBI worked just as well as whole breast radiotherapy. In the initial studies, investigators relied on the placement of many catheters in the breast tissue (interstial brachytherapy). Newer techniques will hopefully provide the same good results but will deliver the radiation in faster and/or more convenient ways. This could increase interest in APBI and allow additional clinical trials that test the safety and effectiveness of the newer approaches. These newer approaches could increase quality of life for many women with breast cancer.
Investigators at Stanford University Medical Center are currently offering an IRB approved clinical trial that uses three new approaches for APBI. These three approaches are:
Intraoperative Radiotherapy (IORT) - 1 day
Intracavitary Brachytherapy (MammoSite) - 5 days
3-D Conformal/External Beam Radiotherapy - 5 days
The Stanford trial is led by Dr. Frederick Dirbas, Assistant Professor of Surgery, and by Dr. Donald Goffinet, Professor of Radiation Oncology. For further information about the trial please contact Janelle Maxwell or Triona Dolphin at (650) 498-7740.
Twitter-enabled Mobile Messaging for Smoking Relapse Prevention (Tweet2Quit)
Tweet2Quit is an innovative smoking cessation intervention that combines real-time online peer-to-peer support with auto messaging. In a three-group randomized controlled trial, the investigators will compare: 1) usual care, 2) Tweet2Quit-coed, and 3) Tweet2Quit-Women only.
Stanford is currently not accepting patients for this trial.
Stanford Investigator(s):
Intervention(s):
- drug: NRT
- behavioral: Web Guide
- behavioral: Tweet2Quit
Eligibility
Inclusion Criteria:
- Are 21-59 years of age
- Are smoking 5+ cigarettes/day and 100+ cigarettes in one's lifetime
- In the preparation stage of quitting smoking
- Are English speaking
- Have a mobile phone with an unlimited texting plan and internet access (via mobile
phone)
- Text at least once a week
- Are a social media user
- Have an active email account
- Lives in the continental USA
Exclusion Criteria:
- Have certain medical conditions that are contraindicated for nicotine replacement
therapy: pregnant, breast feeding, a recent heart attack, an irregular heartbeat, high
blood pressure not controlled with medication, skin allergies to adhesive tape or
serious skin problems, taking a prescription medicine for depression, and/or any other
medical conditions that would prevent you from completing this study.
- Are an illicit hard drug user or regular marijuana user
- Share a household with someone else or has an immediate family member who has already
enrolled in the study currently or in the past or if the participant has already been
enrolled or failed to pass the screening once already since October 2016
- Participated in Tweet2Quit between 2012-2013 in a Twitter group and was not an active
tweeter (<1 week)
- Fails to provide valid forms of all the required personal contact information
Ages Eligible for Study
21 Years - 59 Years
Genders Eligible for Study
All
Not currently accepting new patients for this trial
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Judith J Prochaska, PhD, MPH
650-724-3608
Not Recruiting
What's New
Stanford’s APBI trial has now been expanded to include women with ductal carcinoma in situ (DCIS). Please call 650-498-7740 for more information.